Pacific Biosciences of California, Inc.
PACBPacific Biosciences of California, Inc. develops and commercializes advanced DNA sequencing systems and technologies. Known for its long-read sequencing capabilities, the company provides solutions for genomic research, clinical applications, and agricultural research, enabling detailed and accurate analysis of complex genetic structures.
Company News
The global genomics data analysis market is projected to grow from $6.85 billion in 2024 to $28.74 billion by 2034, driven by advancements in sequencing technologies, personalized medicine demand, and AI-driven analytics.
PacBio will participate in two upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference in Boston and Morgan Stanley 23rd Annual Global Healthcare Conference in New York, with live webcasts available.
The long-read sequencing market is projected to grow significantly, driven by the increasing adoption of next-generation sequencing technologies in genomic research, precision medicine, and genetic disease diagnostics. The U.S. market is expected to surge, benefiting from federal funding and a well-established infrastructure supporting these appl...
The global metagenomics market is projected to reach $6.71 billion by 2031, growing at a CAGR of 15.6% from 2024 to 2031. Key drivers include declining sequencing costs, increasing agricultural genomics focus, and genome mapping initiatives. Challenges include high instrument costs and a shortage of skilled professionals.
PacBio announced the conclusion of an independent investigation into employment and cybersecurity allegations, reporting its Q1 2025 financial results, and the launch of a newborn screening initiative in Thailand using its HiFi whole genome sequencing technology.
